Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Limited

Tetsuya Kawano

Yumiko Ishii

Yasushi Mima

Kenji Nakamura

Masafumi Misaki

Naoru Hamaguchi

Hiroyoshi Koyama

Kenichiro Kiyoshima

Kazuhiro Doken

Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Dry coated tablet

Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.

Orally disintegrable tablet

A dry-coated tabletcomprises an inner corewhich contains an active component and an outer layerwhich contains powdery solid components and coats the inner core. Openingsandare formed in circular surfacesandrespectively of the inner core, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer, and the inner surfaceof the outer layerpenetrates in the openingsand

Dry-coated tablet

The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from 'a solid preparation containing only an insulin sensitizer as an active ingredient'. The solid preparation comprises 'a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol' and &#x201c;a part containing an active ingredient other than an insulin sensitizer&#x201d;.

Solid preparation

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.

Growing community of inventors

Osaka, Japan

Tetsuya Kawano